Icariside II (ICS II), a phosphodiesterase 5 inhibitor (PDE 5-I), is a major ingredient of Epimedium brevicornum, with wide spectrum of neuroprotective properties. However, little is known about the potential beneficial effect of ICS II on neuronal cell proliferation, and its possible underlying mechanism remains still unclear. We hypothesized that the beneficial effect of ICS II on neuron-like highly differentiated rat pheochromocytoma (PC12) cell proliferation is correlated with the nitric oxide (NO) signaling pathway and its upstream of PI3K/AKT pathway. PC12 cells were treated with ICS II alone or together with L-NMMA, H89, KT-5823, and/or LY294002 (the inhibitor of NOS, PKA, PKG, PI3K, respectively). It was found that ICS II concentration-dependently promoted PC12 cells proliferation, and cell cycle analysis showed that the proportion of ICS II-treated PC12 cells in S phase was higher than that of control. Moreover, ICS II at the appropriate concentration (100 mM) not only increased nNOS expression, NO production, but also enhanced cGMP content and PKG activity. The addition of L-NMMA and KT-5 823 significantly inhibited the effects of ICS II on nNOS expression, NO production and PKG activity. Furthermore, LY294002 significantly decreased p-AKT level, NOS activity, NO production and nNOS expression, but it did not affect iNOS expression. These findings demonstrate that the beneficial effect of ICS II on neuronal cell proliferation, and its possible underlying mechanisms are, at least partly, through activating AKT/nNOS/ NO/cGMP/PKG signaling pathway.
Introduction
Neurodegenerative diseases such as Alzheimer's disease (AD) are characterized by a loss of neurons in the brain and few effective treatments for many neurological disorders were discovered (Hoch et al., 2017) . Currently, the effective way to replace neural tissue loss is through transplantation of neural stem cells. However, their procurement, the requirement for immune suppression and low number upon harvest make them limited for clinical applications (Lee et al., 2017; Marsh and Blurton-Jones, 2017) . Therefore, it is important to explore new and alternative therapies for the treatment of neurodegenerative diseases.
Accumulating evidence reveals that phosphodiesterase 5 (PDE 5), a PDE enzyme that hydrolyses the cyclic guanosine monophosphate (cGMP), can affect neuronal cell survival, and it may play a part in neurodegenerative diseases when the function is abnormal (Gomez-Vallejo et al., 2016) . In the central nervous system, cGMP plays a vital role in regulating on the action of nitric oxide (NO), which is a gaseous free radical that acts as an important sign of intracellular and extracellular processes, and it is intracellularly synthesized by three isoforms of the NO synthase enzyme (NOS), including the endothelial form (eNOS), inducible form (iNOS), and the neuronal form (nNOS), which is present in neurons and glial cells. Thereby, it produces NO under physiological conditions (Calvo and Beltran Gonzalez, 2016; Chen et al., 2017) . Moreover, there is mounting evidence from clinical and experimental trials that indicates that NO-cGMP-PKG is the central mechanism of a network of signaling pathways (Balderas et al., 2014) . Furthermore, experimental researches have shown that PDE 5 inhibitor (PDE 5-I) such as sildenafil, not only possesses anti-erectile dysfunction in the peripheral system, but also ameliorates neurological deficits and promotes neurogenesis and recovers function after ischemic stroke in rats (Charriaut-Marlangue et al., 2014; Rybalkina et al., 2010) . However, due to single target and serious adverse reaction, the clinical application of PDE 5-I for neurodegenerative diseases is largely limited. While, traditional Chinese medicine (TCM) possesses the characteristics of multiple targets, less adverse reaction, and provides rich resources to explore promising PDE 5-I. Hence, TCM will be another important strategy for screening PDE 5-I (Jin et al., 2014) . For these reasons, recent researches have focused on TCM to explore PDE 5-I from its phytochemicals to promote neuronal cell proliferation, which provides new prospects for developing innovative approaches for therapies of neurodegenerative diseases.
Icariside II (ICS II) is a major active component of Herba Epimedii, which is one of the traditional Chinese herbs for treating various diseases . ICS II has been found to promote osteoblastic proliferation, ameliorate streptozotocin-induced diabetic nephropathy in diabetic rats, alleviate ischemiareperfusion-induced hippocampal injury in gerbils and inhibit the growth of the various cancer cell lines Luo et al., 2015; Tian et al., 2015; Yan et al., 2014) . Interestingly, our previous study showed that pre-treatment with ICS II for 48 h exhibited protective effect on H 2 O 2 -induced PC12 cells death via inhibiting PDE activity and NO content in vitro . At the same time, our pilot experiment found that treatment with ICS II for 72 h promotes PC12 cell proliferation, but its mechanism remains still unclear. Hence in this study, we applied inhibitors of the NO signaling pathway to elucidate the effect of ICS II on PC12 cell proliferation, and further to explore its possible underlying mechanism. We confirm that ICS II may target nNOS and inhibit PDE 5 activity to result in NO increase, and thereby it promotes neuron-like pheochromocytoma PC12 cell proliferation.
Materials and methods

Chemical and regents
Icariside II (ICS II, purity 98%) was obtained from Nanjing Zelang Medical Technology Corporation Ltd. (Nanjing, China). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco (Grand Island, NY, USA). BrdU cell proliferation ELISA Kit and propidium iodide (PI) were obtained from Abcam (Cambridge, UK). Total nitric oxide synthase (NOS) activity assay kit, PDE5 activity assay kit, cGMP, cyclic adenosine monophosphate (cAMP), cGMP-dependent protein kinase G (PKG) and cAMP-dependent protein kinase A (PKA) measurement kits were obtained from Shanghai Jianglai Company (Shanghai, China). Griess Reagent was purchased from Invitrogen (Eugene, OR,USA), N G -Monomethyl-L-arginine Monoacetate Salt (L-NMMA), H89 and KT-5 823 were from Sigma-Aldrich (St Louis, MO, USA). LY294002 and anti-p-serine/threonine kinase (AKT) primary antibodies were from Cell Signaling Technology (USA), anti-nNOS, anti-iNOS primary antibodies were obtained from Abcam (Cambridge, UK).
Cell culture
PC12, a cell line derived from rat adrenal medulla, is considered as an approriate model to investigate neuronal cell proliferation in vitro, and was purchased from American Type Culture Collection. The cells were cultured in DMEM medium with 10% FBS, L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 mg/ml) at 37 C with 5% CO 2 in a humidified atmosphere.
BrdU incorporation assay
The PC12 cells at 37 C were treated with different concentrations of ICS II (25, 50, and 100 mM) for 72 h 100 mM L-NMMA, a total NOS activity inhibitor, 10 mM H89, a PKA inhibitor, and 5 mM KT-5823, a PKG inhibitor, were pre-treated with cells for 1 h before different concentrations of ICS II treatment, respectively. Following incubation, cell growth was determined by BrdU incorporation assay. Cellular morphologic variation was detected by phase contrast microscopy.
Cell cycle assay
Cell cycle of PC12 treated with ICS II were detemined by flow cytometry analysis (Quan et al., 2017) . Briefly, after PC12 cells were treated with indicated concentrations of ICS II (25, 50 and 100 mM)
for 72 h, Cells were centrifuged at 1 000 rpm for 5 min and supernatant was removed. Thereafter, 200 mg/ml PI, 0.1% sodium azide, 0.1% Triton-X100 and 10 mg/ml RNAses were added and cells were stained in the dark for 2 h. The cell cycle (G1, G2, S phases) was quantificated by Cell Quest (BD Biosciences) and data were analyzed by Modfit software (BD Biosciences).
Measurement of total NOS activity
In brief, PC12 cells were pre-treated with or without 100 mM L-NMMA for 1 h before 100 mM ICS II treatment for 72 h. After cells were washed with PBS twice and total NOS activity was detected using the total NOS Kit according to the manufacturer's guidance.
Measurement of NO
PC12 cells were pre-treated with or without 100 mM L-NMMA for 1 h before 100 mM ICS II treatment for 72 h. NO production was determined as nitrite/nitrate by Griess Reagent (Molecular Probes, Invitrogen, Eugene, OR, USA) (Zhai et al., 2014) . Briefly, equivalent of 1% sulphanylic acid and 0.1% N-(1-naphthyl) ethylenediamine were added to the samples and then incubated for 30 min at room temperature. The final absorbance values were determined at 540 nm wavelength. The NO content of each sample was calculated by a standard curve generated according to the manufacturer's guidance.
ELISA assay
The PC12 cells were treated with H89 (10 mM), or KT-5 823 (5 mM) 1 h before treatment with ICS II at different concentrations of (25, 50, and 100 mM) for 72 h. Cells were lysed in the lysis buffer and centrifuged for 20 min at 2000 rpm at 4 C. The supernatant was maintained at -80 C for the follow determination. Thereafter, cGMP and cAMP levels, PKG and PKA activities were quantified in these samples using the according kits following the procedures recommended by the manufacturer, respectively.
PDE5 activity assay
PDE5 activity was assayed using quantitative phosphorus colorimetric assay kit. Briefly, cells were treated as described above, and then lysed using lysis buffer and centrifuged for 5 min at 16,000 g. The supernatant was stored at -80 C for subsequent measurement. The sample's total PDE5 activity, and nonspecific activity were determined using the phosphorus colorimetric quantitative assay kit according to the manufacturer's indications. Specific PDE5 activity ¼ total PDE5 activity-nonspecific PDE5 activity.
Western blot analysis
In brief, cells were treated with or without ICS II and L-NMMA or 50 mM LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor.
After 72 h, cells were trypsinized, and the cell pellet was gathered. Protein concentration was determined by the BCA protein assay kit. Following the electrophoresis, protein blots were transferred onto a PVDF membrane. Thereafter, 5% non-fat milk was used to block the membrane for 2 h at room temperature and incubated overnight at 4 C with the suitable primary antibody: anti-nNOS (1:1 000), antiiNOS (1:1 000), anti-p-Akt (1:1 000), anti-Akt (1:1 000). After incubated with horseradish peroxidase-conjugated secondary antibodies for 2 h at room temperature with shaking, the bands of protein were developed with the ECL Western Blot reagent, and the blots was visualized using Davinch-Chemi™ imaging system and the relative band optical intensity was quantified using Quantity One 1-D analysis software v4.52 (BioRad, Philadelphia, USA).
Statistical analysis
All results were analyzed by the SPSS 17.0 statistics software (Chicago, IL, USA) and were expressed as mean ± standard deviation (SD). All results were obtained from at least three separate experiments. A one-way ANOVA was used for multiple comparisons. When ANOVA test results for all data were significant, post-hoc least significant difference (LSD) was used to determine the individual differences. A value of P < 0.05 was considered significant.
Results
ICS II promoted PC12 cell proliferation
The results showed that ICS II concentration-dependently promoted proliferation of PC12 cells compared with control cells (without ICS II). To elucidate the possible involvement of PKA or PKG pathway in the beneficial effects of ICS II on proliferation of PC12 cells, PC12 cells were pre-incubated with or without L-NMMA, H89, or KT-5 823 for 1 h before incubated with ICS II at various concentrations. It was found that pre-incubation with L- NMMA or KT-5 823 almost abolished the effects of ICS II on proliferation of PC12 cells, but H89 had no effects on cellular proliferation. L-NMMA, H89, and KT-5 823 did not affect cell growth when they were treated alone [F (8,18 )¼ 192.950, P < 0.001] (Fig. 1A) . These finding indicated that PKG pathway was involved in the beneficial effect of ICS II on PC12 cells, and the facilitated effect of ICS II on cell proliferation was also verified by morphologic observations of cells (Fig. 1B) .
Effects of ICS II on PC12 cell cycle
To clarify the effect of ICS II on PC12 cell cycle, cell cycle was determined by flow cytometry. Cell cycle analysis showed that compared with control (S phase cells was 13.56%), ICS II (25, 50, 100 mM) elevated S phase cells to 17.20%, 22.61%, 27.56%, respectively [F (3,8)¼ 16.501, P < 0.001] (Fig. 2) . The results indicated that ICS II promoted cell proliferation in the S phase in a concerntrationdependent manner. The percentage of cells in S phase of the cell cycle. Data are presented as the mean ± S.D. of three independent experiments. * P < 0.05, ** P < 0.01 versus the control case.
ICS II increased NOS activity and NO production
To elucidate whether the NO signaling pathway is involved in the beneficial effect of ICS II on PC12 cells, NOS, known as an enzyme catalyze L-arginine to NO, were firstly determined after treatment with ICS II for 72 h. The total NOS activity (including nNOS and iNOS) and the NO content in ICS II-treated cells were significantly increased compared with those in the control cells. However, these effects were dramatically abolished by L-NMMA, a pharmacological inhibitor for NOS activity [F (3,8)¼ 69.637, P < 0.001; F (3,8)¼ 54.480, P < 0.001] (Fig. 3A and B) . Consistently, the protein expression level of nNOS enzyme was also significantly increased by ICS II compared to the control. However, there was no effect on iNOS enzyme. It was worth noting that the nNOS expression was almost completely inhibited when L-NMMA was added together with ICS II, but the iNOS expression was not affected [F (3,8) (Fig. 3C and D) .
Effects of ICS II on cGMP and cAMP levels, PDE5, PKG and PKA activities
To further investigate whether the PKG pathway is involved in the beneficial effect of ICS II on PC12 cells, the PDE5 activity, intracellular cGMP and cAMP levels, PKG and PKA activities were determined in the present study. ICS II (25, 50 and 100 mM) were capable of decreasing PDE5 activity compared with control, however, KT-5 832 exerted no effect on PDE5 activity [F (5,11) ¼ 389.361, P < 0.001] (Fig. 4A) . Furthermore, ICS II increased intracellular cGMP level and PKG activity, however, the ICS IImediated effect on PKG activity was diminished, while the effect on cGMP level was not altered when KT-5 832 was added together with ICS II [F (5,12)¼ 55.364, P < 0.001; F (5,12)¼ 12.143, P < 0.001] (Fig. 4B and C) . ICS II exhibited no effect on cAMP level and PKA activity, and there were no effects on cAMP level and PKA activity when H89 was added together with ICS II [F (5,12)¼ 0.020, P¼1.000; F (5,12)¼ 0.021, P¼1.000] (Fig. 4D and E) .
LY294002 inhibited p-AKT level, NOS activity, nNOS expression and NO production induced by ICS II
To explore whether PI3K/AKT pathway plays a role in ICS II induced cell proliferation and NO production, we primarily detected the expression of p-AKT. The results showed that ICS II significantly elevated the p-AKT level. Notably, LY294002, a specific inhibitor of PI3K, not only dramatically attenuated the p-AKT level compared with ICS II alone [F (3,8) ¼ 95.424, P < 0.001], but also (Fig. 5) .
Discussion
The main finding in the current study demonstrated that (1) ICS II promotes PC12 cell proliferation and the proportion of ICS IItreated PC12 cells in S phase was higher than that of control; (2) The beneficial effect of ICS II on neuronal cell proliferation is due to increasing NO level; (3) ICS II not only activates AKT, an upstream target of nNOS, to result in the increase of NO level, but also inhibits PDE5 activity to suppress the degradation of NO.
Our previous study demonstrated that ICS II significantly reduced the impairments of learning and memory in AD model mice and exerted protective effect on cerebral ischemiareperfusion injury in vivo through inhibition of PDE5 Yan et al., 2017) . Notably, we found that ICS II exhibited neuroprotective effect, which was related to inhibit cGMP- specific PDE5 and increase NO content in vivo in the first time . Hence, we hypothesized that ICS II promotes neuronal cell proliferation likely through mediating NO/cGMP/PKG pathway. The results in this study showed that ICS II could concentrationdependently promote neuronal cells proliferation as evidenced by BrdU assay. Furthermore, cell cycle analysis indicated that ICS II significantly promoted PC12 cells proliferation at S phase as evidenced by flow cytometry. Furthermore, cell cycle analysis indicated that ICS II significantly promoted PC12 cells proliferation at S phase as evidenced by flow cytometry. As PC12 cells are highly differentiated neuron-like cells commonly employed as an instructive model for studying the underlying mechanisms of neuronal proliferation and differentiation (Attiah et al., 2003) , our findings demonstrated that ICS II concerntration-dependently can promote neuronal cell proliferation at S phase, and have no effects on any other cell cycle phases. However, a recent study reported that, in glioblastoma cells (U87MG and A172 cells), ICS II can induce cell cycle arrest at G1 phase leading to fewer cells in G2/M phase (Quan et al., 2017) . This may be attributed to differences between PC12 and glioblastoma cells. Interestingly, the proliferationfacilitated effect could be reversed by NOS inhibitor and PKG inhibitor, but not by PKA inhibitor. Therefore, we confirmed that the promoting effect of ICS II on neuronal cell proliferation is related to NO/cGMP/PKG pathway.
Recently, accumulating evidence demonstrates that PDE 5 is an important enzyme which can down-regulate NO signaling by hydrolyzing cGMP (Mergia and Stegbauer, 2016) . NO activates soluble guanylate cyclase and then leads to formation of cGMP which may regulate neurogenesis and enhance cell proliferation (Akassoglou, 2005; Navarra et al., 2004) . PDE 5-I plays an important role in activatiing the NO/cGMP pathway and markedly elevates cGMP levels in brain (Booth et al., 2017) . PKG, as the downstream kinase of cGMP, normally activates specific proteins . This study showed that ICS II is a PDE5-I as evidenced by decreasing PDE5 activity, caused intracellular accumulation of NOS level and NO content, indicating that ICS II increased the total NOS activity, sequentially augmented the NO content. The role of NO/cGMP signaling pathway in regulating facilitated effect of ICS II on neuronal cell proliferation was consistent with the report that ICS II increases intracellular cGMP levels through the enhancement of nNOS expression and NOS activity in peripheral system (Zhang et al., 2012) . Moreover, L-NMMA, the inhibitor of NOS, remarkably attenuated total NOS activity and NO production. Furthermore, ICS II increased nNOS expression, and this effect was blocked by L-NMMA. Intriguingly, there was no significant difference of iNOS expression, suggesting that NO derived from nNOS, but not the iNOS isoform, and nNOS is the main target in ICS II-facilitated neuronal cells proliferation.
In spite of the relationship between ICS II and NO has been confirmed, however, the upstream and downstream of NO during the process of neuronal cell proliferation by ICS II remains still unknown. However, the findings in this study showed that ICS II increased cGMP level and PKG activity, but not cAMP level and PKA activity, indicating that PDE5-related cGMP signaling might participate in facilitated effect of ICS II on neuronal cell proliferation. Interestingly, KT-5 832 reversed the increase in PKG activity, but not cGMP level, suggesting that ICS II might up-regulate cGMP, and then increase the PKG production, which is consistent with the report that PKG is downstream of cGMP (Singhvi et al., 2016) . Furthermore, it is known that serine/threonine protein kinase AKT plays an efficient role in numerous processes of cell metablism, differentiation, survival, proliferation, and so on (Davis and Pennypacker, 2017; Zhang et al., 2016) . Furthermore, AKT signaling has been proved to be involved in neuronal growth and proliferation, and it further phosphorylate nNOS. Therefore, it is further concluded that the mechanism of beneficial effects of ICS II are due to involvement of AKT and NO signaling pathway. As expected, the results demonstrated that LY294002 abrogated the increase in NOS activity and NO production by ICS II, and further dramatically blocked the nNOS expression but not iNOS, indicating that nNOS may be a target of ICS II during its promotion of neuronal cell proliferation, and AKT is the upstream of nNOS.
Conclusions
In conclusion, we elucidated that ICS II promots neuronal cell proliferation in a concentration-dependent manner, and its possible underlying mechanism are, at least partly, involved in PI3K/AKT and NO/cGMP/PKG signaling pathways locating in the upstream and downstream of nNOS, respectively. ICS II will be a promising candidate for treating neurodegenerative diseases, such as AD, etc.
Conflict of interest
The authors declare no conflict of interests.
